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Received October 22, 2014; accepted February 6, 2015AbstractBackground: To assess the impacts of age, performance status, and clinical stage on advanced urothelial carcinoma of the bladder (UCB) in
patients treated with different treatment modalities.
Methods: This retrospective study included 160 patients who underwent radical cystectomy (RC) with/without neoadjuvant or adjuvant che-
moradiotherapy, palliative chemotherapy/radiotherapy/chemoradiotherapy (CRT), and transurethral resection of bladder tumor (TURBT)
monotherapy for advanced UCB in one institution from 2000 to 2010. KaplaneMeier analysis was used to calculate the survival distributions of
overall survival (OS). The quality of life of the patients was also analyzed.
Results: The median age of the patients was 74.0 years, and the mean survival interval was 31.5 months. The 2-year OS was significantly
different among the three modalities [RC > TURBT monotherapy, odds ratio (OR): 1.86, 95% CI: 1.17e2.96, p ¼ 0.009; CRT > TURBT
monotherapy, OR: 1.65, 95% CI: 1.06e2.57, p ¼ 0.026]. There were no significant differences in the 5- and 10-year OS rates between the three
treatment modalities. Those younger than 76 years receiving RC had a significantly better 2-year OS than those undergoing CRT and TURBT
monotherapy (RC > TURBT monotherapy, OR: 2.38; 95% CI: 1.30e4.33, p ¼ 0.005). The number and duration of re-hospitalizations were
highest in the CRT group and lowest in the TURBT group.
Conclusion: The short- and long-term OS rates of the three modalities were similar in those older than 76 years. Therefore, patients younger than
age 76 years are likely to have a better outcome undergoing radical cystectomy for advanced UCB.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Bladder cancer is the second most prevalent malignancy of
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assand 14,880 deaths in the United States in 2012,1 and 2003 new
cases and 807 deaths in Taiwan in 2012.2 Typically, the risks
of bladder cancer increase with age, with an average age at
diagnosis of 65 years.3 Among patients with urothelial carci-
noma of the bladder (UCB), 20e40% will present with, or will
develop, muscle-invasive disease.4 Radical cystectomy (RC)
for advanced UCB is the gold standard for local control and
increased survival in patients with muscle-invasive tumors.5
Elderly patients with advanced UCB may be ineligible for
radical surgery due to comorbid conditions, limitedociation. All rights reserved.
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oping complications.6 Even though advances in surgical
techniques have improved perioperative care and made RC
feasible in elderly patients,7,8 they may be denied radical
surgery due to their age alone.9,10
Advanced age is associated with poorer outcomes in pa-
tients treated with radical cystectomy. Nielsen et al3 reviewed
the records of 888 patients with advanced UCB who under-
went radical cystectomy and pelvic lymph node dissection in
three institutions for localized disease, finding advanced age to
be independently and significantly associated with more
pathologically advanced disease and poorer bladder-specific
mortality after the surgery. In a previous report of Goffin
et al,11 bladder-sparing radiotherapy with concurrent chemo-
therapy was shown to be feasible in patients aged 70 years or
over with a good performance status, although this was not
entirely complication-free.
The management of advanced UCB in elderly patients is an
important, controversial, and challenging problem. The goal of
this retrospective study was to compare the overall survival
(OS) and the quality of life of elderly patients receiving three
different treatment modalities for advanced UCB in Taiwan.
2. Methods
This retrospective study was conducted using the
Comprehensive Tri-Service General Hospital Urologic
Oncology database after approval by the hospital's Institutional
Review Board. The study population consisted of 160
consecutive patients diagnosed with advanced UCB between
January 2000 and December 2010 at the Tri-Service General
Hospital, Taipei, Taiwan. Patients who had a histological
diagnosis other than urothelial carcinoma were excluded from
the study, and those with clinical stage T2-T4N0-N2M0-M1
UCB, based on pathological specimens, were included. The
TNM classification for UCB was used according to the 7th
edition of the American Joint Committee on Cancer/Union
International Cancer TNM classification.
Three treatment modalities were used for all 160 patients,
including radical cystectomy (RC) with/without neoadjuvant
or adjuvant chemotherapy, palliative chemotherapy, radio-
therapy, or chemoradiotherapy (CRT), and transurethral
resection of bladder tumor (TURBT) monotherapy.
In order to validate the associations between different
treatment modalities and OS in a larger population, we took
data from the Longitudinal Health Insurance Database
(LHID2000) of Taiwan. The LHID2000 includes all the
original claims data and registration files for 1,000,000 in-
dividuals randomly sampled from the 2000 Registry for
Beneficiaries (n ¼ 23.72 million) of the Taiwan National
Health Insurance (NHI) program. The Taiwan National Health
Research Institute reported that there was no significant dif-
ference in the sex distribution between the sampled enrollees
in the LHID2000 and the complete list of enrollees under the
NHI program. Cases included advanced UCB patients  18
years of age [International Classification of Disease, 9th
edition, Clinical Modification (ICD-9-CM code 188)] duringvisits to ambulatory care centers (including the outpatient
departments of hospitals and clinics) between 2002 and 2008.
We assigned the first bladder cancer diagnosis as the index
date. In order to increase the validity of the advanced bladder
cancer diagnosis, we only included advanced bladder cancer
cases that consisted of at least two bladder cancer diagnoses,
with receipt of TURBT procedures at least three times (ICD-9-
CM codes 57.4 and 57.49). A total of 699 cases were matched
of advanced bladder cancer who received three different
treatment modalities, including 201 patients with RC (ICD-9-
CM codes 57.7, 57.71, and 57.79), 114 patients with CRT, and
384 cases receiving TURBT monotherapy (ICD-9-CM codes
57.4 and 57.49).
Quality of life was determined by the frequency and
duration of rehospitalizations after initial management. Sur-
vival rates were calculated as the time from the initial diag-
nosis of UCB to the date of last contact or death. The
KaplaneMeier method12 was used to calculate survival dis-
tributions, and all data analyses were performed using SPSS
version 11.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05
was considered to indicate statistical significance.
3. Results
Of the 160 patients enrolled in this study, 122 were men,
and the median age was 74.0 years. The Eastern Cooperative
Oncology Group (ECOG) performance scores were 0 for 12 of
the 160 patients, 1 for 87 patients, 2 for 45 patients, 3 for 15
patients, and 4 for one patient. The clinical T stage of UCB
was T2 for 96 patients, T3 for 30 patients, and T4 for 34
patients. One-hundred and thirty-one patients were initially
clinically N0, and 19 patients had visceral metastasis at the
initial diagnosis. Forty-two patients received RC, 60 patients
CRT, and 58 patients TURBT monotherapy (Table 1).
Of the 160 patients, 113 patients had died by the time of
analysis, and the mean overall survival interval was 31.5 ± 3.2
months, including 38.5 ± 3.6 months with RC, 26.2 ± 2.2
months with CRT, and 31.8 ± 3.3 months with TURBT
monotherapy. The 2-year OS was 57.1% for the RC group,
35.0% for the CRT group, and 49.0% for the TURBT mono-
therapy group. The 2-year OS rate was significantly different
among the three treatment modalities. Cox regression analysis
showed the hazard ratios (HRs) [95% confidence intervals
(CIs)] were 0.39 (0.21e0.70) and 0.63 (0.38e1.03) in RC (vs.
TURBT) and CRT (vs. TURBT) after adjusting the comor-
bidity and confounding factors (Figure 1A). There were no
significant differences in the 5- and 10-year OS rates among
the three treatment modalities (Table 2).
We then divided the patients into three age groups: younger
than 75 years, 76 years, and 77 years, and analyzed the dif-
ferences in OS among these patient groups. The results
showed that the 2-year OS rate was statistically significantly
different only in the younger than 75 years group and 76 years
group, and that those younger than 76 years had the largest log
rank value (Table 3). Therefore, we set 76 years as the cut-off
age for the elderly population and analyzed the OS among
each treatment modality. In accordance with the finding that
Table 1
Baseline patient characteristics (n ¼ 160).
n (%) p
All (n ¼ 160)  76 y (n ¼ 89) > 76 y (n ¼ 71)
Median age (y) 74.00 ± 6.24 63.48 ± 8.89 82.38 ± 4.28 <0.001
Sex 0.377
Male 122 (76.3) 65 (73.0) 57 (80.3)
Female 38 (23.7) 24 (27.0) 14 (19.7)
ECOG
performance
status
0.005
0 12 (7.5) 12 (13.5) 0 (0)
1 87 (54.4) 47 (52.8) 40 (56.3)
2 45 (28.1) 21 (23.6) 24 (33.8)
3 15 (9.4) 8 (9.0) 7 (9.9)
4 1 (0.6) 1 (1.1) 0 (0)
T category 0.553
T2 96 (60.0) 49 (55.1) 44 (62.0)
T3 30 (18.8) 21 (23.6) 12 (16.9)
T4 34 (21.2) 19 (21.3) 15 (21.1)
N category 0.018
N0 130 (81.3) 66 (74.2) 64 (90.1)
N1 30 (18.7) 23 (25.8) 7 (9.9)
M category 0.149
M0 141 (88.1) 75 (84.3) 66 (93.0)
M1 19 (11.9) 14 (15.7) 5 (7.0)
Treatment
modality
0.001
RC 42 (26.2) 34 (38.2) 8 (11.3)
CRT 60 (37.5) 28 (31.5) 32 (45.0)
TURBT 58 (36.3) 27 (30.3) 31 (43.7)
CRT ¼ palliative chemotherapy or radiotherapy or chemoradiotherapy;
ECOG ¼ Eastern Cooperative Oncology Group; RC ¼ radical cystectomy
with or without neoadjuvant or adjuvant chemoradiotherapy;
TURBT ¼ transurethral resection of bladder tumor.
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those receiving CRT and TURBT monotherapy within 2 years,
there were no significant differences in OS of each survival
interval among the different treatment modalities in the elderly
population (older than 76 years) in our study (Figure 1B).
In accordance with our study results from the patients in
our hospital database, the data from LHID2000 also showed
that the overall advanced bladder cancer patients receiving RC
had the best OS in comparison with CRT and TURBT mon-
otherapy significantly. Cox regression analysis showed the
HRs (CIs) were 0.55 (0.42e0.71) and 0.99 (0.71e1.38) in RC
(vs. TURBT) and CRT (vs. TURBT) after adjusting risk fac-
tors (Figure 1C). Moreover, although the elderly population
aged older than 76 years with RC from the LHID2000 also had
a better OS than did those with CRT and TURBT monotherapy
(log rank test, p ¼ 0.016; Figure 1D), it seems that there was
no significant difference in OS among the RC, CRT, and
TURBT groups after a 5-year interval.
Eighty-nine patients were younger than 76 years,
including 34 who received RC, 28 who received CRT, and 27
who received TURBT monotherapy. The mean survival in-
terval was 39.5 ± 3.5 months in the RC group, 20.3 ± 2.1
months in the CRT group, and 33.2 ± 3.2 months in the
TURBT monotherapy group. The OS duration was 41.9 ± 3.9months in the RC group, 21.1 ± 2.2 months in the CRT
group, and 35.3 ± 3.3 months in the TURBT monotherapy
group. The 2-year OS of those younger than 76 years
receiving RC was better than those of patients receiving CRT
and TURBT monotherapy [RC > TURBT monotherapy, odds
ratio (OR): 2.38; 95% CI: 1.30e4.33, p ¼ 0.005;
CRT > TURBT monotherapy, OR: 1.66; 95% CI: 0.87e3.17,
p ¼ 0.13]. As compared with the overall population, the 5-
year OS rates of those younger than 76 years showed no
significant differences, while those who received RC treat-
ment had a slightly better outcome than those who received
CRT treatment; and no significant differences were seen in
the 10-year OS rates.
Of the 71 patients older than 76 years of age, eight received
RC, 32 received CRT, and 31 received TURBT monotherapy.
The mean survival interval was 34.1 ± 3.0 months in the RC
group, 31.4 ± 2.2 months in the CRT group, and 30.4 ± 2.1
months in the TURBT monotherapy group. The CSS was
42.7 ± 4.2 months in the RC group, 31.0 ± 3.0 months in the
CRT group, and 41.5 ± 3.5 months in the TURBT mono-
therapy group. In contrast to the overall patients and younger
patients, in the older patients group there were no significant
differences in OS among the three treatment modalities, even
within each survival interval. The mean numbers of rehospi-
talizations were 5.1, 5.6, and 1.3, with durations of 61.75 days,
62.88 days, and 8.4 days after RC, CRT, and TURBT mono-
therapy, respectively (Table 4).
4. Discussion
We found that advanced UCB patients younger than 76
years receiving RC had a superior OS compared with those
receiving TURBT monotherapy or CRTwithin an interval of 2
years. However, there were no significant differences among
the three treatment modalities in OS of an interval > 2 years.
Of the patients older than 76 years, TURBT monotherapy had
CSS and OS rates similar to that of RC, which is the gold
standard management for the loco-regional control of
advanced UCB.13
RC is effective in achieving local tumor control and may
cure patients, with reported 5-year CSS rates ranging from
40% to 60%.13,14 Although patients with advanced UCB
should therefore undergo RC, Gore et al15 reported a marked
underuse of RC, with only 21% of patients undergoing the
procedure. Hollenbeck et al16 reported that, despite relative
increases in the proportion of younger-age cohorts undergoing
RC during the course of the study, the proportion of those
older than 80 years undergoing RC remained constantly lower,
at 10e12%, suggesting that advances in surgical techniques
and perioperative management have not been extended to very
elderly patients.
In our study, 26.25% of the advanced UCB patients un-
derwent RC, which is comparable to previous reports.
Furthermore, 38.2% of those younger than 76 years and
11.27% of those older than 76 years received RC treatment,
indicating a decreasing trend of RC among advanced UCB
patients with increasing age. This may be due to the elderly
Figure 1. KaplaneMeier analyses of (A) comparisons of overall survival among different treatment modalities for the overall individuals of our cases, the results of
which showed significant differences within the survival interval of 2 years after adjusting the comorbidity and confounding factors; (B) the elderly population
(>76 years of age) from our cases, showing no statistically significant differences among the different treatment modalities; (C) comparisons of overall survival
among different treatment modalities for the overall patients of LHID2000, the results of which showed significant differences among RC, CRT, and TURBT
monotherapy after adjusting for risk factors; and (D) the elderly population (>76 years of age) from LHID2000, showing that differences in OS among the different
treatment modalities were insignificant after a 5-year interval. CRT ¼ chemoradiotherapy; RC ¼ radical cystectomy; TURBT ¼ transurethral resection of bladder
tumor.
Table 2
Comparisons of 2-year, 5-year, and 10-year OS rates among the different treatment modalities of the patients overall.
Pearson Chi-square RC versus TURBT 95% CI CRT versus TURBT 95% CI
p OR p OR p
2-y OS 8.238 0.016 1.857 0.009 1.167e2.955 1.651 0.026 1.062e2.566
5-y OS 1.587 0.452 1.375 0.209 0.837e2.259 1.146 0.578 0.709e1.851
10-y OS 1.256 0.534 1.314 0.301 0.783e2.207 1.243 0.389 0.758e2.040
CRT ¼ palliative chemotherapy or radiotherapy or chemoradiotherapy; OS ¼ overall survival; RC ¼ radical cystectomy with or without neoadjuvant or adjuvant
chemoradiotherapy; TURBT ¼ transurethral resection of bladder tumor.
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from adverse events, and shorter life expectancy. In the current
study, the 2-year OS was significantly better ( p ¼ 0.017) for
patients younger than 76 years. This suggests that aggressive
and extended treatment strategies should be given to patients
of younger age, which was < 76 years in our study. RC had the
best OS within 2 years of the three modalities
(RC > CRT > TURBT monotherapy). In accordance with our
results, Peyromaure et al17 and Skinner et al18 also suggested
that advanced UCB patients could be considered for RC only
when they had a life expectancy of at least 2 years.
Among the patients who were older than 76 years in the
current study, more patients in the TURBT monotherapy
group had an ECOG performance score of 1. Although therewas not enough statistical power to conclude if there was a
difference between the treatments, more patients were at the
clinical T2 stage as compared with the CRT and RC groups
(TURBT monotherapy > CRT > RC; p < 0.01). In addition,
more patients had clinical N0 disease at the initial diagnosis in
the TURBT monotherapy group than in the CRT and RC
groups, although significant difference was not present. Based
on the trend of the results of our present study, the findings
agree with previous general viewpoints on the management of
aged patients at high risk of perioperative morbidity and
delayed recovery from aggressive surgery. However, some
elderly patients with more advanced UCB, such as those with
T3- and T4- stage UCB, may have been considered for
aggressive RC treatment over the more conservative treatment
Table 3
Comparisons of differences in OS among the patients aged 75 years, 76 years,
and 77 years with a survival interval of 2 years.
 75 y Log rank >75 y Log rank
TURBT 13 7.8; p ¼ 0.020 14 3.621; p ¼ 0.164
CRT 19 20
RC 15 6
 76 y Log rank >76 y Log rank
TURBT 14 8.145; p ¼ 0.017 13 3.430; p ¼ 0.180
CRT 19 20
RC 16 5
 77 y Log rank >77 y Log rank
TURBT 16 5.347; p ¼ 0.069 11 2.985; p ¼ 0.265
CRT 20 19
RC 18 3
CRT ¼ palliative chemotherapy or radiotherapy or chemoradiotherapy;
OS ¼ overall survival; RC ¼ radical cystectomy with or without neoadjuvant
or adjuvant chemoradiotherapy; TURBT ¼ transurethral resection of bladder
tumor.
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despite their poor performance status.
The prognosis for advanced UCB is poor, with reported 5-
year CSS and OS rates ranging from 20% to 50% regardless of
the type of treatment.6,19 Considering the multiple comorbid-
ities, short life expectancy, and quality of life of elderly pa-
tients, bladder-sparing treatments such as chemotherapy,
radiotherapy, TURBT monotherapy, or a combination of these
therapies may be considered first. Clark et al20 reported that
RC and orthotopic urinary diversion can be offered safely to
carefully selected elderly patients. In the current study, the OSTable 4
Treatment modalities of patients older than 76 years.
n (%)
RC (n ¼ 8) CRT
(n ¼ 32)
TURBT
(n ¼ 31)
p
ECOG performance
status
0.792
1 4 (50) 17 (53.1) 19 (61.3)
2 4 (50) 11 (34.4) 9 (29.0)
3 0 (0) 4 (12.5) 3 (9.7)
T category <0.001
T2 2 (25) 15 (46.9) 27 (87.1)
T3 5 (62.5) 5 (15.6) 2 (6.45)
T4 1 (12.5) 12 (37.5) 2 (6.45)
N category 0.627
N0 7 (87.5) 28 (87.5) 29 (93.6)
N1 1 (12.5) 4 (12.5) 2 (6.4)
M category >0.99
M0 8 (100) 29 (90.6) 29 (93.6)
M1 0 (0) 3 (9.4) 2 (6.4)
Mean rehospitalizations after treatment
Number of
rehospitalizations
5.1 (3.18) 5.6 (3.52) 1.3 (1.64) <0.001
Total duration (d) 61.75 (37.59) 62.88 (53.31) 11.13 (14.98) <0.001
CRT ¼ palliative chemotherapy or radiotherapy or chemoradiotherapy;
ECOG ¼ Eastern Cooperative Oncology Group; RC ¼ radical cystectomy
with or without neoadjuvant or adjuvant chemoradiotherapy;
TURBT ¼ transurethral resection of bladder tumor.of those older than 76 years showed no significant difference
between RC and TURBT monotherapy in different survival
intervals. This suggests that the benefits of aggressive and
relatively conservative treatment strategies are similar for
elderly patients, and although RC can be performed in certain
elderly patients, TURBT monotherapy may have an effect
similar to that of RC. According to our results, we suggest that
TURBT monotherapy is suitable for advanced UCB in patients
older than 76 years.
Although UCB is a chemo-sensitive neoplasm, the CSS and
OS rates in patients with advanced or metastatic disease are
low and the prognosis is poor.21 Even with more advanced
UCB, elderly patients are significantly less likely to receive
adjuvant chemotherapy.20 Among the patients older than 76
years in the current study, 45.0% received CRT, of whom
81.2% died, with a survival interval of 31.4 months. In our
elderly patients, the mortality rate was highest in the CRT
group (CRT > RC > TURBT monotherapy:
81.2% > 75% > 64.3%). However, OS was not significantly
different among the different treatment modalities.
Considering the quality of life of elderly patients, we
analyzed the number and duration of rehospitalizations after
the different treatment modalities. The mean number of
rehospitalizations was highest in the CRT group and lowest in
the TURBT monotherapy group. In addition, the total reho-
spitalization duration was longest in the CRT group and
shortest in the TURBT monotherapy group. Furthermore, on
the basis of similar oncological outcomes of the three treat-
ment modalities for patients older than 76 years, the cost
effectiveness of TURBT monotherapy was better than that of
both RC and CRT.
Herr22 reported that radical TURBT monotherapy for
advanced UCB is an acceptable bladder-sparing treatment
strategy that may produce oncological outcomes equivalent to
RC in appropriately selected patients. Complete resection of
the tumor is likely to be the most significant factor, and can
achieve a 5-year OS rate comparable with that of RC in
selected patients.23 Recently, synchronous chemotherapy with
fluorouracil and mitomycin C combined with radiotherapy has
been shown to significantly improve loco-regional control of
advanced UCB, with a reported 5-year CSS rate of 48% in one
study.6 This is in contrast to our findings, which may be due to
the more advanced age of our patients with more adverse
toxicity of the chemotherapy.
There are certain limitations when interpreting the findings
of this study. Firstly, the retrospective assessment of advanced
UCB in elderly patients may have led to comparison bias due
to patient and treatment selection. Secondly, the sample size of
the study was relatively small. Increasing the sample size may
increases statistical power, but might require a multi-center
study to obtain enough sample size. Thirdly, the enrolled pa-
tients with stage II to IV advanced UCB, patients of different
treatment modalities followed individual department protocol
and image study. Fourthly, any comparisons of the three
treatment modalities derived from nonrandomized cohorts
may result in bias, and some patients were treated with a mix
of treatment modalities that may make comparison between
474 C.-L. Chen et al. / Journal of the Chinese Medical Association 78 (2015) 469e474groups to establish causality more difficult. Finally, because
the database used in this study lacked a collection of certain
pathologic features (such as lymphovascular invasion) and
other assessment data (such as frailty, nutrition, and comor-
bidity), it was impossible to perform analysis controlling for
those different factors. According to our results, we found
patients had a better outcome when a cut-off age was set at 
76 years for the selection of radical cystectomy for advanced
UCB in our patient population.
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